The outlook for Keya Healthcare, 1) however, is that Keya Ark will launch a commercial product in 2021. In the prospectus, it cites a report from burning knowledge consulting that the company's core product, deep pulse score, is one of the first class III AI medical devices certified by the State Food and Drug Administration as commercializable in China. ② On the market front, China's medical device market is huge and has grown rapidly in recent years. According to insight consulting, China's medical device market size has grown from approximately 3125.5 billion yuan in 2015 to 7789.3 billion yuan in 2020, with a CAGR of 20.0%, and deep learning medical devices have begun to penetrate this huge market. (iii) Although the current penetration rate is still very low (less than 0.01% in 2021, according to INSIGHT CONSULTING), with the continuous development of deep learning technology, according to INSIGHT CONSULTING, it is expected that China's deep learning medical device market regulation will grow from approximately 489.8 million yuan in 2021 to approximately 20.1 billion yuan, with a CAGR of 153.2%. In summary, AI diagnostics are still in the early stages of development; for example, according to the Prospectus, deep pulse scoring will provide new diagnostics that even the most experienced physicians cannot provide. These diagnostics are not yet available in the clinic, carry significant risks, and will have some issues with acceptance by physicians.